Asunto(s)
Industria Farmacéutica , Neoplasias , Medicina de Precisión , Industria Farmacéutica/economía , Industria Farmacéutica/métodos , Industria Farmacéutica/organización & administración , Detección Precoz del Cáncer , Humanos , Medicina Molecular/economía , Medicina Molecular/métodos , Medicina Molecular/organización & administración , Neoplasias/diagnóstico , Neoplasias/tratamiento farmacológico , Medicina de Precisión/economía , Medicina de Precisión/métodosAsunto(s)
Humanos , Masculino , Femenino , Técnicas de Diagnóstico Molecular/normas , Técnicas de Diagnóstico Molecular/tendencias , Técnicas de Diagnóstico Molecular , Patología Molecular/métodos , Patología Molecular/normas , Patología Molecular/tendencias , Medicina Molecular/métodos , Técnicas de Diagnóstico Molecular/métodos , Patología Molecular/organización & administración , Medicina Molecular/organización & administración , Medicina Molecular/normas , Biología Molecular/métodos , Biología Molecular/organización & administración , Biología Molecular/normasRESUMEN
The High Throughput Biomedicine (HTB) unit at the Institute for Molecular Medicine Finland FIMM was established in 2010 to serve as a national and international academic screening unit providing access to state of the art instrumentation for chemical and RNAi-based high throughput screening. The initial focus of the unit was multiwell plate based chemical screening and high content microarray-based siRNA screening. However, over the first four years of operation, the unit has moved to a more flexible service platform where both chemical and siRNA screening is performed at different scales primarily in multiwell plate-based assays with a wide range of readout possibilities with a focus on ultraminiaturization to allow for affordable screening for the academic users. In addition to high throughput screening, the equipment of the unit is also used to support miniaturized, multiplexed and high throughput applications for other types of research such as genomics, sequencing and biobanking operations. Importantly, with the translational research goals at FIMM, an increasing part of the operations at the HTB unit is being focused on high throughput systems biological platforms for functional profiling of patient cells in personalized and precision medicine projects.